CETP Gene Test (Cholesteryl Ester Transfer Protein)

• Identify whether you carry CETP variants that change CETP secretion or activity and thereby raise or lower HDL cholesterol, shift HDL particle size, and alter triglyceride distribution between HDL and triglyceride rich lipoproteins.
• Help explain patterns such as very high HDL cholesterol, discordance between HDL levels and cardiovascular risk, or unexpected lipid responses to lifestyle or treatment, by revealing how your neutral lipid transfer system is wired.
• Add context to cardiovascular risk, since some CETP variants associated with higher HDL do not necessarily reduce coronary risk, while others contribute to CETP‑related hyperalphalipoproteinaemia with large HDL particles and complex risk profiles.
• Inform personalised strategies around lipid targets, emphasis on LDL and apoB lowering versus HDL raising, and potential fit with therapies that interact with CETP related pathways or are influenced by HDL particle size and function.
• Clarify your baseline cholesteryl ester and triglyceride transfer architecture alongside other lipid genes, so long term cardiovascular plans can be built on both genetics and real time lipids rather than HDL numbers alone.

CETP encodes cholesteryl ester transfer protein, a glycoprotein of about 476 amino acids synthesised mainly in the liver and secreted into plasma. CETP circulates bound to lipoproteins and acts as a shuttle for neutral lipids, primarily cholesteryl esters and triglycerides, between lipoprotein particles.

In human plasma, CETP transfers cholesteryl esters from HDL to apoB‑containing lipoproteins such as VLDL and LDL, in exchange for triglycerides moving from VLDL and LDL back into HDL. This heteroexchange of neutral lipids tends to deplete cholesteryl esters from HDL, enrich HDL with triglycerides, and enrich VLDL and LDL with cholesteryl esters, thereby influencing HDL size and catabolism and the cholesterol content of atherogenic lipoproteins. Loss‑of‑function CETP variants reduce this transfer and lead to high HDL cholesterol and large, cholesteryl ester rich HDL particles.

CETP binds to lipoproteins, particularly HDL, via hydrophobic interactions with the HDL surface lipids, and bridges HDL to apoB‑containing particles. Its elongated structure forms a tunnel through which cholesteryl esters and triglycerides move from one lipoprotein core to another. CETP is therefore a central mediator of neutral lipid exchange in plasma.

Functionally, CETP transfers cholesteryl esters out of HDL into VLDL and LDL in exchange for triglycerides. This process can lead to cholesteryl ester‑depleted, triglyceride‑rich HDL that is more rapidly catabolised, lowering HDL cholesterol levels, while increasing the cholesteryl ester content of VLDL and LDL, which may promote atherogenesis when LDL and apoB are high. At the same time, CETP participates in reverse cholesterol transport by facilitating the movement of HDL‑derived cholesteryl esters into particles that are taken up by the liver. The net impact of CETP activity on cardiovascular risk depends on the balance between these pathways and the broader lipoprotein environment.

CETP directly shapes HDL quantity and quality and influences the distribution of cholesterol and triglycerides across lipoproteins. Genetic CETP deficiency or strong activity‑lowering variants produce CETP‑related hyperalphalipoproteinaemia, characterised by markedly elevated HDL cholesterol and large, cholesteryl ester‑rich HDL particles. This primary hyperalphalipoproteinaemia is usually asymptomatic and often discovered incidentally, but affected individuals can still develop coronary artery disease, showing that very high HDL is not automatically protective.

Common CETP polymorphisms such as TaqIB, I405V, and others are associated with differences in HDL cholesterol, CETP mass and activity, HDL particle size, and sometimes longevity phenotypes, with B2 and certain I405V genotypes linked to higher HDL and larger HDL particles in some populations. However, large human genetic studies and CETP inhibitor trials suggest that raising HDL by lowering CETP activity does not consistently reduce cardiovascular events unless LDL and apoB are also lowered. This has led to a shift in focus from simply raising HDL cholesterol to improving apoB containing lipoproteins and HDL function.

It is easy to assume that CETP testing and standard lipid panels tell you the same story, but they capture different layers of your biology. Lipid panels, apoB, and LDL particle measures show how your lipids are behaving now; coronary calcium and imaging show current arterial impact; CETP genotyping reveals how efficiently your system tends to move cholesteryl esters and triglycerides between HDL and apoB lipoproteins over the long term.

This distinction matters because you can have CETP variants that elevate HDL and yet remain at non‑trivial cardiovascular risk if LDL, apoB, blood pressure, and inflammation are not well controlled. Conversely, you can have lower HDL with relatively favourable CETP genotypes but low overall risk if apoB, lifestyle, and blood pressure are well managed. CETP results provide a context for interpreting "high HDL" and deciding how much weight to give HDL in your risk assessment.

The influence of CETP variants is shaped by your apoB burden, diet, body composition, and other genes rather than by the gene alone, which means you have meaningful room to change the trajectory. Several modifiable factors can either buffer or amplify any genetic tendency.

• ApoB and LDL cholesterol levels: High apoB and LDL amplify the potential atherogenic impact of CETP mediated cholesteryl ester transfer into apoB particles. When apoB is low, CETP variation and HDL changes are less likely to translate into major cardiovascular risk differences.
• Triglycerides and remnant cholesterol: Diet, insulin sensitivity, and alcohol intake drive VLDL and remnant levels. High triglycerides increase the substrate for CETP and can lead to more triglyceride rich, cholesteryl ester poor HDL, especially in those with higher CETP activity.
• Body weight and insulin sensitivity: Central obesity and insulin resistance worsen triglycerides, HDL, and remnant profiles and interact with CETP to shape HDL size and function. Weight loss and improved insulin sensitivity often have larger effects on risk than CETP genotype.
• Other lipid and longevity genes: Variants in LPL, APOA5, APOE, and others influence triglyceride rich lipoproteins and can either accentuate or offset CETP related lipid changes. CETP is a part of the broader polygenic architecture of lipid traits and healthy longevity.
• Medication choices: Statins, ezetimibe, PCSK9 inhibitors, and triglyceride lowering therapies reduce apoB and remnant burden and can diminish the practical importance of CETP variation. Direct CETP inhibitors markedly raise HDL but have had mixed cardiovascular trial results, illustrating that CETP is only one piece of risk management.

Yes, and this is common. Many people have CETP variants that raise HDL or change particle size without clinical symptoms. CETP‑related hyperalphalipoproteinaemia, caused by biallelic or heterozygous pathogenic variants that markedly reduce or prevent CETP secretion, often presents only as unexpectedly high HDL cholesterol on routine testing, with no physical signs.

Even in these conditions, coronary artery disease can still occur, particularly if other risk factors such as smoking, high LDL, hypertension, or diabetes are present. Conversely, people without CETP variants can develop very high HDL from secondary causes or from lifestyle interventions without having CETP‑related hyperalphalipoproteinaemia. CETP status is therefore a context signal rather than a guarantee of protection or risk.

Common CETP genotypes mainly differ in how they affect CETP secretion, mass, and activity, which in turn influence HDL cholesterol levels, HDL particle size, and lipid exchange rates.

• Loss of secretion or marked loss‑of‑function variants (biallelic or dominant): Prevent CETP secretion or greatly reduce its release into plasma, causing autosomal dominant or recessive CETP‑related hyperalphalipoproteinaemia with markedly elevated HDL cholesterol and large cholesteryl ester‑rich HDL particles. These variants can produce very high HDL but do not uniformly guarantee low coronary risk.
• Partial activity reduction variants: Missense variants that reduce CETP secretion or activity to a lesser degree cause milder hyperalphalipoproteinaemia with moderately elevated HDL cholesterol and relatively large HDL particles. Most of these have modest clinical effects that depend on the rest of the risk profile.
• TaqIB (B1/B2) polymorphism: A common intronic polymorphism where the B2 allele (absence of the TaqI site) is generally associated with lower CETP mass and activity, higher HDL cholesterol, and larger HDL particles and has been linked in some populations to reduced coronary risk and longer life, though not consistently across all cohorts.
• I405V and other intronic and promoter variants: I405V and several other polymorphisms have been associated with higher HDL cholesterol, larger HDL particles, and longevity phenotypes in some studies and are often part of "longevity syndrome" profiles when combined with favourable HDL and other genes.

For DNA based CETP testing, preparation is straightforward because your genotype does not change with diet, exercise, or medication. The key step is ensuring CETP is tested within a clinically relevant panel, such as a hyperalphalipoproteinaemia or cardiometabolic panel, and that you have or will obtain current lipid data to interpret results properly.

CETP genotyping from blood or saliva does not require fasting. However, fasting is usually recommended before lipid and triglyceride blood tests so that HDL, LDL, non‑HDL, and remnant measures are accurate and comparable over time. You should follow any instructions about fasting, alcohol, and medication timing that your clinician or testing provider gives for these companion tests.

A CETP test is most valuable when the result will influence how you and your clinician interpret high HDL, refine cardiovascular risk, or consider familial hyperalphalipoproteinaemia, and when it sits within a clear prevention or treatment plan. It is less helpful when ordered in isolation without considering other lipids and risk factors.

• Very high HDL cholesterol or suspected hyperalphalipoproteinaemia: If HDL cholesterol is markedly elevated without obvious secondary causes, CETP testing can clarify whether CETP‑related hyperalphalipoproteinaemia is present and guide how much reassurance to take from high HDL.
• Discordant HDL and risk profile: When HDL is high but other risk markers or family history are concerning, CETP genotyping can help explain the pattern and emphasise focus on apoB and LDL rather than relying on high HDL as protection.
• Strong family history of early coronary artery disease or longevity with unusual lipid patterns: CETP variants can form part of a "longevity" or "lipid resilience" profile in families with long lived members and high HDL, or help explain early disease despite favourable HDL numbers.
• Comprehensive cardiometabolic prevention: In individuals building a detailed prevention plan with genomic data, CETP sits alongside LPL, APOA5, APOE, LDLR, and others to refine strategies for diet, exercise, lipid targets, and treatment combinations.